with Steve Pratt, Author of the hit book Earn It

CASE STUDY

How a Global Pharmaceutical Company Made Complex Science Worth Listening To

How JAR turned complex pharmaceutical research into a 10-episode podcast people actually stayed to hear.
Industry
Pharmaceuticals

Company size

Global Enterprise

Website

Key Takeaways

  • The challenge: A global pharmaceutical company needed to make complex medical research understandable and engaging while navigating strict regulatory requirements and scientific accuracy.
  • JAR’s solution: Using the JAR System, we developed a 10-episode podcast that translated complicated science into accessible stories, supported by expert research, creative production and medical review processes.
  • Audience engagement: The podcast achieved 75%+ average episode consumption, demonstrating that listeners spent meaningful time with complex scientific content.
  • Business value: The project created a reusable content platform across audio, video and social media, helping the company communicate its expertise beyond individual episodes while working within pharmaceutical review requirements.

overview

JAR helped a global pharmaceutical company turn complex medical science into an accessible, engaging podcast that made important research easier to understand and kept audiences listening.

Business Objective

A global pharmaceutical company wanted to create more meaningful conversations around the research, scientists and persistence behind medical progress.

The company works on some of medicine’s hardest problems. Its researchers spend years studying disease, developing new therapies and trying to solve questions that rarely have simple answers.

That expertise created a communications challenge.

Pharmaceutical research is complex. The language can be technical. The science needs to be precise. And anything published by a pharmaceutical company has to move through a demanding medical, legal and regulatory review process.

The company did not need another place to publish corporate information or research summaries.

It needed a format that could make serious science understandable and interesting without oversimplifying it.

The goal was to bring audiences closer to the people, questions and persistence behind pharmaceutical innovation.

The Solution

JAR worked with the company to develop an audience-first pharmaceutical podcast built around the human questions inside complex medical research.

We used the JAR System to define the job the podcast needed to do, the audience it needed to serve and the result the company wanted to create.

That meant resisting the obvious version of the show: scientists talking about company research.

Instead, we looked for the bigger question inside each subject.

What problem are researchers trying to solve?

Why is it difficult?

What have scientists learned?

What could that mean for patients and medicine?

And why should someone outside the company care?

From there, JAR developed the editorial strategy, researched topics, sourced and prepared guests, wrote scripts and interview questions, produced the audio and video, created supporting social content and managed distribution.

The editorial challenge was simple to describe and difficult to execute:

Make pharmaceutical science accessible without making it simplistic.

Every episode had to pass two tests.

Is the science accurate?

Would someone who does not work for the company actually want to hear it?

JAR also designed the production workflow around pharma’s extensive approval requirements, building medical, legal, regulatory and communications review into the process from the beginning rather than treating compliance as the final hurdle before publication.

That gave the team room to make a better show while still meeting the standards required of a global pharmaceutical company.

The Impact

The result was a 10-episode first season built around scientists, medical experts and human stories.

Listeners consumed more than 75% of the average episode.

That matters because the subject matter was not naturally easy listening. These were conversations about complex science, research and medicine. The audience stayed anyway.

The series also gave the company a long-form platform for talking about pharmaceutical innovation outside the limits of a press release, research summary or corporate post.

Each conversation produced additional video and social assets, extending the value of the original interview across the company’s owned channels.

But the bigger impact was strategic.

The JAR System gave the team a shared filter for making decisions before production started.

How We Used the JAR System

Job

Make complex pharmaceutical science understandable and interesting without turning the show into corporate communications.

Audience

People interested in science, medicine and medical progress, including healthcare professionals, researchers and scientifically curious listeners.

Result

Build understanding and trust by giving audiences more time with the scientists, ideas and human stories behind pharmaceutical innovation.

Those three decisions shaped everything that followed:

  • Episode topics
  • Guest selection
  • Research
  • Scripts
  • Interview questions
  • Titles
  • Medical and legal review
  • Social content
  • Distribution
  • Measurement

Instead of asking, “What does the company want to talk about?” we could ask, “Does this help the show do its job for the audience?”

That sounds like a small distinction.

It changes the show.

What Changed

Before After
Let’s make a podcast about our research. Let’s make complex science worth spending time with.
Start with what the company wants to say. Start with what the audience wants to understand.
Explain the science. Find the human question inside the science.
Feature internal experts. Choose the people who can make the subject interesting and clear.
Treat compliance as a final approval step. Build medical, legal and regulatory review into the production system.
Publish an episode. Create audio, video and social assets from the same conversation.
Measure downloads. Measure whether people actually stay and listen.

What This Means for Marketers

The lesson is not that every pharmaceutical company needs a podcast.

It is that expertise alone is not a content strategy.

Brands with complicated products, research or subject matter often assume the audience needs more explanation.

Sometimes they do.

But explanation is not enough.

People need a reason to care before they will spend time understanding something complicated.

That means finding the question, tension, person or consequence that makes the information matter.

It also means deciding what the content is supposed to do before choosing the format.

For marketers working in regulated or highly technical industries, the approval process matters too.

Compliance cannot be bolted onto the end of creative development.

If medical, legal and regulatory review are part of the production system from the start, you can protect accuracy without discovering at the eleventh hour that the interesting parts have to disappear.

The other lesson is measurement.

A download tells you somebody started.

Consumption tells you whether the content earned their time.

For a show dealing with complicated pharmaceutical science, 75%+ average episode consumption was a much more useful signal than reach alone.

Listeners consumed more than three-quarters of the average episode, showing strong engagement with complex pharmaceutical, scientific and medical subject matter.

The first season created a substantial library of long-form pharmaceutical and science storytelling rather than a one-off corporate content campaign.

Each episode became the foundation for additional video and social content, extending the value of the company’s scientists, experts and stories across owned channels.

JAR built medical, legal, regulatory and communications review into the production workflow, helping protect scientific accuracy without allowing the approval process to strip the personality out of the show.

75%+
Average episode consumption
10
Episodes in the first season
1
Long-form content platform across audio, video and social